Savara reports second quarter 2021 financial results and provides business update

Austin, texas--(business wire)--savara inc. (nasdaq: svra), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the second quarter ending june 30, 2021 and provided a business update. “over the last 9 months we streamlined our portfolio, reduced and restructured the organization, and significantly strengthened the balance sheet so that we could focus solely on advancing the pivotal phase 3 impala 2 clinical trial,” said matt paul
SVRA Ratings Summary
SVRA Quant Ranking